Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice.
The "mechanistic target of rapamycin" (mTOR) is a central controller of growth, proliferation and/or motility of various cell-types ranging from adipocytes to immune cells, thereby linking metabolism and immunity. mTOR signaling is overactivated in obesity, promoting inflammation and insul...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d9f98ed9519749d696812e9679e5562a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d9f98ed9519749d696812e9679e5562a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d9f98ed9519749d696812e9679e5562a2021-11-18T08:24:33ZBeneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice.1932-620310.1371/journal.pone.0092684https://doaj.org/article/d9f98ed9519749d696812e9679e5562a2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24710396/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203The "mechanistic target of rapamycin" (mTOR) is a central controller of growth, proliferation and/or motility of various cell-types ranging from adipocytes to immune cells, thereby linking metabolism and immunity. mTOR signaling is overactivated in obesity, promoting inflammation and insulin resistance. Therefore, great interest exists in the development of mTOR inhibitors as therapeutic drugs for obesity or diabetes. However, despite a plethora of studies characterizing the metabolic consequences of mTOR inhibition in rodent models, its impact on immune changes associated with the obese condition has never been questioned so far. To address this, we used a mouse model of high-fat diet (HFD)-fed mice with and without pharmacologic mTOR inhibition by rapamycin. Rapamycin was weekly administrated to HFD-fed C57BL/6 mice for 22 weeks. Metabolic effects were determined by glucose and insulin tolerance tests and by indirect calorimetry measures of energy expenditure. Inflammatory response and immune cell populations were characterized in blood, adipose tissue and liver. In parallel, the activities of both mTOR complexes (e. g. mTORC1 and mTORC2) were determined in adipose tissue, muscle and liver. We show that rapamycin-treated mice are leaner, have enhanced energy expenditure and are protected against insulin resistance. These beneficial metabolic effects of rapamycin were associated to significant changes of the inflammatory profiles of both adipose tissue and liver. Importantly, immune cells with regulatory functions such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) were increased in adipose tissue. These rapamycin-triggered metabolic and immune effects resulted from mTORC1 inhibition whilst mTORC2 activity was intact. Taken together, our results reinforce the notion that controlling immune regulatory cells in metabolic tissues is crucial to maintain a proper metabolic status and, more generally, comfort the need to search for novel pharmacological inhibitors of the mTOR signaling pathway to prevent and/or treat metabolic diseases.Kassem MakkiSolenne TarontOlivier Molendi-CosteEmmanuel BouchaertBernadette NeveElodie EuryStéphane LobbensMyriam LabaletteHélène DuezBart StaelsDavid DombrowiczPhilippe FroguelIsabelle WolowczukPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 4, p e92684 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Kassem Makki Solenne Taront Olivier Molendi-Coste Emmanuel Bouchaert Bernadette Neve Elodie Eury Stéphane Lobbens Myriam Labalette Hélène Duez Bart Staels David Dombrowicz Philippe Froguel Isabelle Wolowczuk Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. |
| description |
The "mechanistic target of rapamycin" (mTOR) is a central controller of growth, proliferation and/or motility of various cell-types ranging from adipocytes to immune cells, thereby linking metabolism and immunity. mTOR signaling is overactivated in obesity, promoting inflammation and insulin resistance. Therefore, great interest exists in the development of mTOR inhibitors as therapeutic drugs for obesity or diabetes. However, despite a plethora of studies characterizing the metabolic consequences of mTOR inhibition in rodent models, its impact on immune changes associated with the obese condition has never been questioned so far. To address this, we used a mouse model of high-fat diet (HFD)-fed mice with and without pharmacologic mTOR inhibition by rapamycin. Rapamycin was weekly administrated to HFD-fed C57BL/6 mice for 22 weeks. Metabolic effects were determined by glucose and insulin tolerance tests and by indirect calorimetry measures of energy expenditure. Inflammatory response and immune cell populations were characterized in blood, adipose tissue and liver. In parallel, the activities of both mTOR complexes (e. g. mTORC1 and mTORC2) were determined in adipose tissue, muscle and liver. We show that rapamycin-treated mice are leaner, have enhanced energy expenditure and are protected against insulin resistance. These beneficial metabolic effects of rapamycin were associated to significant changes of the inflammatory profiles of both adipose tissue and liver. Importantly, immune cells with regulatory functions such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) were increased in adipose tissue. These rapamycin-triggered metabolic and immune effects resulted from mTORC1 inhibition whilst mTORC2 activity was intact. Taken together, our results reinforce the notion that controlling immune regulatory cells in metabolic tissues is crucial to maintain a proper metabolic status and, more generally, comfort the need to search for novel pharmacological inhibitors of the mTOR signaling pathway to prevent and/or treat metabolic diseases. |
| format |
article |
| author |
Kassem Makki Solenne Taront Olivier Molendi-Coste Emmanuel Bouchaert Bernadette Neve Elodie Eury Stéphane Lobbens Myriam Labalette Hélène Duez Bart Staels David Dombrowicz Philippe Froguel Isabelle Wolowczuk |
| author_facet |
Kassem Makki Solenne Taront Olivier Molendi-Coste Emmanuel Bouchaert Bernadette Neve Elodie Eury Stéphane Lobbens Myriam Labalette Hélène Duez Bart Staels David Dombrowicz Philippe Froguel Isabelle Wolowczuk |
| author_sort |
Kassem Makki |
| title |
Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. |
| title_short |
Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. |
| title_full |
Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. |
| title_fullStr |
Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. |
| title_full_unstemmed |
Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. |
| title_sort |
beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/d9f98ed9519749d696812e9679e5562a |
| work_keys_str_mv |
AT kassemmakki beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT solennetaront beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT oliviermolendicoste beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT emmanuelbouchaert beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT bernadetteneve beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT elodieeury beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT stephanelobbens beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT myriamlabalette beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT heleneduez beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT bartstaels beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT daviddombrowicz beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT philippefroguel beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice AT isabellewolowczuk beneficialmetaboliceffectsofrapamycinareassociatedwithenhancedregulatorycellsindietinducedobesemice |
| _version_ |
1718421830768787456 |